Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 14/20 | 0.90 |
| ▸ | BCL2 | P10415 | 9/20 | 0.90 |
| ▸ | MDM4 | O15151 | 1/20 | 0.90 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | BID | P55957 | 1/20 | 0.90 |
| ▸ | BAX | Q07812 | 1/20 | 0.90 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.90 |
| ▸ | ASPH | Q12797 | 1/20 | 0.90 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.90 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.90 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.90 |
| ▸ | BAD | Q92934 | 1/20 | 0.90 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.90 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.90 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.90 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.90 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.90 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.90 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503787 | 0.96 | BCL2L1 (0.89) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL3957570 | 0.96 | HDAC3 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL4892842 | 0.96 | HDAC3 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL3955717 | 0.95 | HDAC3 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540348 | 0.95 | HDAC3 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL4903512 | 0.95 | HDAC3 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL29355185 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL158942 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL170470 | 0.95 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | claimed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | claimed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | claimed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBVIE INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | ABBVIE INC. | 2016-04-14 | — | — | US | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20100087436-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090176785-A1 | METHOD OF TREATING ARTHRITIS | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2L1 953/4885BCL2 520/4885MDM4 630/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20160101109-A1 | METHOD OF TREATING ARTHRITIS | MMP1, COL2A1, MMP13 | BCL2L1 1304/4885BCL2 147/4885MDM4 2663/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | BCL2L1 20/4885BCL2 4/4885MDM4 2603/4885 |
| US-20080076779-A1 | Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members | BCL2, BAX, BCLAF1 | BCL2L1 7/4885BCL2 1/4885MDM4 4169/4885 |
| US-20090176785-A1 | METHOD OF TREATING ARTHRITIS | MMP1, COL2A1, MMP13 | BCL2L1 1304/4885BCL2 147/4885MDM4 2663/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885MDM4 441/4885 |
| US-20100087436-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885MDM4 2097/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | BCL2L1 3/4885BCL2 4/4885MDM4 1653/4885 |
| US-20080182845-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885MDM4 2097/4885 |
| US-20160175316-A1 | METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION | BST2, HLA-C, HLA-B | BCL2L1 233/4885BCL2 94/4885MDM4 2097/4885 |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.